- Home
- PNI vs CING Comparison
PNI vs CING Comparison
Compare PNI & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNI | CING |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.1M | 93.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PNI | CING |
|---|---|---|
| Price | $7.00 | $4.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | 40.4K | ★ 429.3K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 4.76% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.43 | $3.20 |
| 52 Week High | $7.20 | $11.89 |
Technical Indicators
Market Signals| Indicator | PNI | CING |
|---|---|---|
| Relative Strength Index (RSI) | 56.41 | 39.23 |
| Support Level | $6.88 | $3.50 |
| Resistance Level | $7.07 | $6.79 |
| Average True Range (ATR) | 0.08 | 0.49 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 73.68 | 28.33 |
Price Performance
Historical ComparisonAbout PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.